119 related articles for article (PubMed ID: 9922045)
21. In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD.
Memoli B; Grandaliano G; Soccio M; Postiglione L; Guida B; Bisesti V; Esposito P; Procino A; Marrone D; Michael A; Andreucci M; Schena FP; Pertosa G
J Am Soc Nephrol; 2005 Apr; 16(4):1099-107. PubMed ID: 15716332
[TBL] [Abstract][Full Text] [Related]
22. Soluble gp130 is up-regulated in the implantation window and shows altered secretion in patients with primary unexplained infertility.
Sherwin JR; Smith SK; Wilson A; Sharkey AM
J Clin Endocrinol Metab; 2002 Aug; 87(8):3953-60. PubMed ID: 12161539
[TBL] [Abstract][Full Text] [Related]
23. No association of serum levels of interleukin-6 and its soluble receptor components with a genetic variation in the 3'flanking region of the interleukin-6 gene in patients with multiple sclerosis.
Schmidt S; Papassotiropoulos A; Bagli M; Harzheim M; Heun R; Klockgether T
Neurosci Lett; 2000 Nov; 294(3):139-42. PubMed ID: 11072134
[TBL] [Abstract][Full Text] [Related]
24. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
25. Clinical applications of IL6 inhibitors.
Klein B; Lu ZY; Bataille R
Res Immunol; 1992 Sep; 143(7):774-6. PubMed ID: 1439155
[No Abstract] [Full Text] [Related]
26. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor.
Liautard J; Sun RX; Cotte N; Gaillard JP; Mani JC; Klein B; Brochier J
Cytokine; 1997 Apr; 9(4):233-41. PubMed ID: 9112331
[TBL] [Abstract][Full Text] [Related]
27. Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels.
Wonnerth A; Katsaros KM; Krychtiuk KA; Speidl WS; Kaun C; Thaler K; Huber K; Wojta J; Maurer G; Seljeflot I; Arnesen H; Weiss TW
Metabolism; 2014 May; 63(5):647-53. PubMed ID: 24629561
[TBL] [Abstract][Full Text] [Related]
28. Multiple levels of regulation of the interleukin-6 system in stroke.
Acalovschi D; Wiest T; Hartmann M; Farahmi M; Mansmann U; Auffarth GU; Grau AJ; Green FR; Grond-Ginsbach C; Schwaninger M
Stroke; 2003 Aug; 34(8):1864-9. PubMed ID: 12843357
[TBL] [Abstract][Full Text] [Related]
29. GP130 cytokines, interferon, survival and proliferation of human myeloma cells.
Klein B
Eur Cytokine Netw; 1997 Sep; 8(3):323. PubMed ID: 9346376
[No Abstract] [Full Text] [Related]
30. Levels of Soluble Interleukin 6 Receptor and Asp358Ala Are Associated With Cognitive Performance and Alzheimer Disease Biomarkers.
Quillen D; Hughes TM; Craft S; Howard T; Register T; Suerken C; Hawkins GA; Milligan C
Neurol Neuroimmunol Neuroinflamm; 2023 May; 10(3):. PubMed ID: 36810164
[TBL] [Abstract][Full Text] [Related]
31. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
32. [Anti-cytokine therapy for intractable hematologic diseases using monoclonal antibodies].
Nishimoto N
Nihon Naika Gakkai Zasshi; 2004 Feb; 93(2):390-6. PubMed ID: 15007951
[No Abstract] [Full Text] [Related]
33. Soluble glycoprotein 130 (gp130) attenuates OSM- and LIF-induced cartilage proteoglycan catabolism.
Hui W; Bell M; Carroll G
Cytokine; 2000 Feb; 12(2):151-5. PubMed ID: 10671300
[TBL] [Abstract][Full Text] [Related]
34. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach.
French JD; Tschumper RC; Jelinek DF
Leukemia; 2002 Jun; 16(6):1189-96. PubMed ID: 12040452
[TBL] [Abstract][Full Text] [Related]
35. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.
Gu ZJ; De Vos J; Rebouissou C; Jourdan M; Zhang XG; Rossi JF; Wijdenes J; Klein B
Leukemia; 2000 Jan; 14(1):188-97. PubMed ID: 10637495
[TBL] [Abstract][Full Text] [Related]
36. Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression.
Tsukamoto H; Fujieda K; Hirayama M; Ikeda T; Yuno A; Matsumura K; Fukuma D; Araki K; Mizuta H; Nakayama H; Senju S; Nishimura Y
Cancer Res; 2017 May; 77(9):2279-2291. PubMed ID: 28235765
[TBL] [Abstract][Full Text] [Related]
37. Circulating concentrations of soluble interleukin 6 receptors gp80 and gp130 in chronic renal failure and effects of renal replacement therapy.
Frieling JT; van Hamersvelt HW; Wijdenes J; Hendriks T; Sauerwein RW; van Der Linden CJ
Am J Nephrol; 1999; 19(5):571-5. PubMed ID: 10575186
[TBL] [Abstract][Full Text] [Related]
38. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-10 and Gp130 cytokines in human multiple myeloma.
Klein B; Lu ZY; Gu ZJ; Costes V; Jourdan M; Rossi JF
Leuk Lymphoma; 1999 Jun; 34(1-2):63-70. PubMed ID: 10350333
[TBL] [Abstract][Full Text] [Related]
40. The soluble IL-6 receptors: serum levels and biological function.
Montero-Julian FA
Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
